Established in 1986, Ind-Swift is a research driven pharmaceutical group that produces world class finished dosage forms, active pharmaceutical ingredients, and intermediates. Over the years, it has moved forward aggressively, consistently winning new customers worldwide and making inroads into challenging new markets and regions.

Combining cutting edge innovation with dynamic marketing, Ind-Swift has already become a US$ 450 million entity. In fact, it is confidently eyeing the one billion dollar revenue mark by 2020.

The Group's multiple state-of-the-art production facilities, at home and abroad, meet stringent international norms -- including those of the USFDA, UK MHRA, and the WHO.

Ind-Swift Ltd, is listed on the Bombay Stock Exchange and the National Stock Exchange.

Its business successes apart, the group sees itself as a stakeholder in the service to humanity, offering quality pharmaceuticals that mitigate illness and suffering, and contribute to a healthier and better world.